Largest biotech companies by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Amgen leads the 24 biotech companies ranked by total liabilities, at CHF 69.1B, ahead of Gilead Sciences (CHF 30.7B) and Biogen (CHF 9.4B). Figures as of 18 Nov 2026, 16:47 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenCHF 69.1B
- Median
- CHF 592.8M
- Combined market value
- CHF 708.6B
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | CHF 69.1B | CHF 203.8B | CHF 376.78 | 2.41% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | CHF 30.7B | CHF 177.1B | CHF 142.77 | 0.54% down | 33% up | ||
| 3 | BiogenBIIB · Health Care | CHF 9.4B | CHF 31.1B | CHF 210.72 | 0.34% down | 49% up | ||
| 4 | ModernaMRNA · Health Care | CHF 3.1B | CHF 69B | CHF 170.47 | 2.22% down | 755% up | ||
| 5 | BioNTechBNTX · Health Care | CHF 2.6B | CHF 17.6B | CHF 70.94 | 0.85% down | 16% down | ||
| 6 | QiagenQGEN · Health Care | CHF 2.1B | CHF 8.6B | CHF 41.77 | 0.42% down | 12% up | ||
| 7 | Halozyme TherapeuticsHALO · Health Care | CHF 2.1B | CHF 9.3B | CHF 81.74 | 1.02% up | 37% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | CHF 1.2B | CHF 13.9B | CHF 137.12 | 1.98% down | 20% up | ||
| 9 | argenxARGX · Health Care | CHF 1.1B | CHF 49.9B | CHF 794.05 | 0.60% down | 4% up | ||
| 10 | ImmunityBioIBRX · Health Care | CHF 844.3M | CHF 5.9B | CHF 5.55 | 5.19% up | 193% up | ||
| 11 | RepligenRGEN · Health Care | CHF 711.2M | CHF 9.2B | CHF 143.23 | 4.75% up | 5% up | ||
| 12 | Revolution MedicinesRVMD · Health Care | CHF 609.7M | CHF 29.1B | CHF 134.62 | 1.85% down | 131% up | ||
| 13 | ExelixisEXEL · Health Care | CHF 575.9M | CHF 14.2B | CHF 58.24 | 0.84% up | 63% up | ||
| 14 | Bio-TechneTECH · Health Care | CHF 403.4M | CHF 9.6B | CHF 61.31 | 0.13% up | 26% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | CHF 289.5M | CHF 3.4B | CHF 35.05 | 3.55% up | 21% down | ||
| 16 | VaxcytePCVX · Health Care | CHF 267.4M | CHF 7.9B | CHF 49.65 | 0.86% down | 22% up | ||
| 17 | Adaptive BiotechnologiesADPT · Health Care | CHF 242.6M | CHF 3.8B | CHF 23.68 | 1.40% down | 88% up | ||
| 18 | Kodiak SciencesKOD · Health Care | CHF 163.7M | CHF 5.3B | CHF 81.28 | 0.41% down | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | CHF 142.4M | CHF 6.6B | CHF 97.00 | 2.73% up | 340% up | ||
| 20 | Kymera TherapeuticsKYMR · Health Care | CHF 137.5M | CHF 8.7B | CHF 101.57 | 0.86% down | 87% up | ||
| 21 | Scholar Rock HoldingSRRK · Health Care | CHF 133.9M | CHF 4.8B | CHF 39.53 | 4.02% up | 14% up | ||
| 22 | Krystal BiotechKRYS · Health Care | CHF 96.3M | CHF 7.8B | CHF 262.01 | 4.09% up | 46% up | ||
| 23 | ImmunovantIMVT · Health Care | CHF 88M | CHF 5.8B | CHF 28.25 | 0.90% up | 43% up | ||
| 24 | CG OncologyCGON · Health Care | CHF 32.9M | CHF 6.1B | CHF 68.15 | 2.39% up | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8431 CHF).
Questions and answers
Which biotech companies rank first by total liabilities?
Amgen (CHF 69.1B), Gilead Sciences (CHF 30.7B) and Biogen (CHF 9.4B) are the top three of the 24 biotech companies ranked by total liabilities as of 18 Nov 2026, 16:47 UTC.
How many biotech companies are in this ranking?
24 are ranked by total liabilities.
What are these biotech companies worth together?
The 24 biotech companies ranked by total liabilities have a combined market value of CHF 708.6B as of 18 Nov 2026, 16:47 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies by total liabilities”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.